Neuralstem (CUR), a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds.
CUR's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.
It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. CUR is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke.
Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
February 8, 2022
RegMed Investors’ (RMi) closing bell: we had a pitcher in this session, the pitcher's nick-name - Algorithm
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
February 7, 2022
RegMed Investors’ (RMi) closing bell: another bounce, dips got bought yet, the sector could end-up with overbought and volatile bottoms again
February 7, 2022
RegMed Investors’ (RMi) pre-open: question of the session, what’s sustainable?
February 4, 2022
RegMed Investors’ (RMi) closing bell: Volatility fell, volume was lower in a positive cell and gene therapy sector close
February 4, 2022
RegMed Investors’ (RMi) pre-open: picking through the fallen
February 3, 2022
RegMed Investors’ (RMi) closing bell: another wild run
February 3, 2022
RegMed Investors’ (RMi) pre-open: market’s anxiety spills over after disappointing earnings releases
February 2, 2022
RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector got hammered as predicted, when is it wrong to be so right and often?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Neuralstem (CUR) -- 2018 openat at 42.03, slipped to 1.65 as February opened with a low of $1.52 and closed 2/16 at $1.63 ... a relatively flat to lowering chart. What's to watch?
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.